±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 219  |  »Ø¸´: 5
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

lyh447lyh447

ÎÞ³æ (³õÈëÎÄ̳)

[½»Á÷] DGKzeta»ùÒò·½Ã漸¶Î+2009Äê12ÔÂ28ÈÕ

Plasmids and DNA Constructs¡ªRat DGK-IV cDNA was a generous
gift of K. Goto (Yamagata University School of Medicine, Sendai, Japan).
pSREflagDGKIV was excised with EcoRI, and the 3.4-kb fragment
encoding the DGK-IV cDNA was subcloned in the pcDNA3Myc
vector (pCDNAMycDGK-IV). For expression experiments, all constructs
were subcloned in the pEGFPBos vector in the GFP C terminus.
For the MCA construct, pCDNA3MycDGKIV was digested with BstXI/BglII, and the 2.2-kb fragment was subcloned in pEGFPBos. To generate
the ankyrin domains deletion (ANK), pCMV3MycDGKIV was
SacI-digested, blunted, KpnI-digested, and subcloned in pEGFPBos
digested with KpnI/SmaI. Site-directed mutagenesis was performed
using the QuikChange site-directed mutagenesis kit (Stratagene). To
generate the kinase-dead version of the enzyme, Gly-354 was replaced
with Asp as described (25). We designed two mutations in the MARCKS
homology domain; in the first we replaced Ser-259, Ser-266, Ser-271,
and Ser-272 with Ala (mutant Ser 3 Ala), and in the second the same
residues were replaced with Asp (mutant Ser 3 Asp). To mutate the
CRDs, the first conserved His in each of the two CRDs of the protein,
His-98 or His-173, were replaced with Gly either in the wild type
protein or in the Ser 3 Asp mutant. The C-terminal domain (CT)
construct, including the four ankyrin repeats and the PDZ-binding
motif, was generated by PCR with appropriate primers, which included
two restriction sites, SalI and XbaI. The PCR product was subcloned in
the pGEM-T easy vector (Promega) and then excised with SalI/XbaI to
be subcloned in the expression vector pEFBosCX-HA, which was previously
digested with SalI/XbaI.
Cell Lines and Transient Transfections¡ªCOS-7 cells were maintained
in Dulbecco¡¯s modified Eagle¡¯s medium supplemented with 10%
fetal bovine serum and 2 mM glutamine. For transfection, 60¨C80%
confluent cells were transfected with LipofectAMINE (Invitrogen) according to the manufacturer¡¯s instructions. After 24 h cells were harvested,
and each sample was divided into two pellets for immunoblot
and a DAG activity assay. The J-HM1-2.2 cell line was generated by
stable transfection of the human muscarinic subtype 1 receptor in the
Jurkat cell line (29). Cells were maintained in RPMI 1640 medium
supplemented with 10% fetal bovine serum and 2 mM glutamine. Cells
(1.2  107) were transfected by electroporation with 20 g of DNA using
a Gene Pulser (Bio-Rad) at 270 V and a capacitance of 975 microfarads.
Cells were immediately transferred to 30 ml of growth medium and
assayed 24 h later.

Ï£Íû´ó¼ÒÖ§³Ö£¬ÎÒ²»Ì«¶®»ùÒò·½Ã棬ÎÒÏë×ödgk»ùÒòתȾ£¬µ«Õâ·½ÃæÎÒ²»»á£¡£¡£¡Ð»Ð»´ó¼ÒÎÒ£¬ÎÒ°ÉÈ«²¿Äóö£¬Ï£Íû´ó¼Ò°ï°ï棡£¡£¡Íò·Ö¸Ðл£¡£¡£¡

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

sophia622

ľ³æ (СÓÐÃûÆø)

µÚ¶þ¶Î

¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
lyh447lyh447(½ð±Ò+10,VIP+0):·Ç³£¸Ðл£¡£¡£¡ 12-27 00:08
zap65535(½ð±Ò+3,VIP+0):ÖúÈËΪÀÖ 12-27 01:58
ϸ°ûϵºÍ˲ʱתȾ¡ª¡ªCOS-7ϸ°ûϵά³ÖÔÚ¼ÓÈë̥ţѪÇåºÍ2mM¹È°±õ£°·µÄDulbecco ¸ÄÁ¼ EagleµÄÅàÑø»ùÖУ¬ÎªÁËתȾ£¬60%-80%µÄÈÚºÏϸ°û°´ÕÕ˵Ã÷ÊéÓÃLipofectAMINE (Invitrogen)תȾ£¬24СʱºóÊÕ»ñϸ°û£¬Ã¿ÖÖÑùÆ··Ö×°³É2¸öС¹Ü£¬·Ö±ð×öÃâÒß³ÁµíʵÑéºÍDAG»îÐԲⶨ¡£J-HM1-2.2ϸ°ûϵÊÇÓÉJurkatϸ°ûϵÖÐÈËÀàÑÇÐÍ1¶¾Þ¦¼îÊÜÌåÎȶ¨×ªÈ¾²úÉú£¨29£©¡£²úÉúµÄϸ°û±£³ÖÔÚ¼ÓÓÐ10%µḀ̈ţѪÇåºÍ2mM¹È°±õ£°·µÄRPMI 1640ÅàÑø»ùÖС£
20  g µÄ DNAÓÃ270VºÍ975µçÈݵÄÂö³åÆ÷µçת»¯¾¢(1.2   107)ϸ°ûÖУ¬Ï¸°ûѸËÙ×ªÒÆµ½30mlÉú³¤ÅàÑø»ùÖÐÅàÑø24hºó²â¶¨
3Â¥2009-12-26 21:23:21
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 6 ¸ö»Ø´ð

sophia622

ľ³æ (СÓÐÃûÆø)

µÚÒ»¶Î

¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
lyh447lyh447(½ð±Ò+16,VIP+0):ÌØ±ð¸Ðл£¡£¡£¡ 12-27 00:08
ÖÊÁ£DNA¹¹½¨¡ª¡ªÊóDGK-IVµÄcDNAÓÉK.GotoÓÑÇéÌṩ£¨Yamagata University School of Medicine, Sendai, Japan£©pSREflagDgkIVÓÃEcoRIÇи±àÂëDGK-IV cDNAµÄ3.4kbµÄƬ¶ÎÑǿˡµ½pcDNA3MycÔØÌå(pCDNAMycDGK-IV£©¡£ÎªÁ˱í´ïʵÑ飬ËùÓй¹Ôì±»Ñǿˡµ½pEGFPBosÔØÌåGFPµ°°×µÄCÄ©¶ËÉÏ£»ÎªÁËMCAµÄ¹¹½¨£¬ÓÃBstXI/BglIIÏû»¯pCDNA3MycDGKIV£¬Ïû»¯²úÉúµÄ2.2kbµÄƬ¶ÎÑǿˡµ½pEGFPBosÉÏ¡£ÎªÁ˲úÉú궨µ°°×½á¹¹Óòɾ³ý£¨( ANK£©pCMV3MycDGKIVÓÃSacI¡¢KpnI½øÐÐ˫øÇУ¬²¢ÇÒÑǿˡµ½ÓÃKpnI/SmaIÏû»¯µÄpEGFPBosÔØÌåÉÏ¡£ÓÃQuikChange site-directed mutagenesisÊÔ¼ÁºÐ(Stratagene)¼ì²âλµãÖ±½ÓµÄÍ»±ä¡£ÎªÁ˲úÉúøµÄ¼¤Ã¸Ê§»î£¬Gly-354±»AspÌæ´ú£¨25£©¡£ÎÒÃÇÉè¼ÆÁË2¸öÍ»±äÔÚMARCKSͬԴ½á¹¹Óò£¬µÚÒ»¸öλµãÊÇSer-259, Ser-266, Ser-271ºÍSer-272Í»±ä³ÉAla£¨Í»±äSer 3 Asp)£¬µÚ¶þ¸öÏàͬµÄ²Ð»ù±»AspÈ¡´ú£¨Í»±äSer 3 Asp£©¡£ÎªÁËÍ»±äCRDsµ°°×Á½¸öCRDsµÄµÚÒ»¸ö±£ÊصÄHis£ºHis-98 »òHis-173ÔÚÒ°ÉúÐÍÖб»GlyÌæ´ú£¬ÔÚÍ»±äÐÍÖб»Ser 3 Asp¡£CÄ©¶Ë½á¹¹Óò¹¹½¨°üÀ¨Ãª¶¨µ°°×ÖØ¸´ÐòÁкÍPDZ½áºÏ»ùÐò£¬ÓúÏÊʵÄÓÐSalI ºÍXbaIøÇÐλµãµÄÒýÎï½øÐÐPCRÀ©ÔöµÄ·½·¨²úÉú¡£PCRµÄ²úÎïÑǿˡµ½pGEM-T easy£¨Promega£©ÔØÌåÖÐÈ»ºóÓÃSalI/XbaIøÇУ¬È»ºóÑǿˡµ½ÓÃSalI/XbaIøÇеıí´ïÔØÌåpEFBosCX-HAÉÏ¡£
2Â¥2009-12-26 21:08:07
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

lyh447lyh447

ÎÞ³æ (³õÈëÎÄ̳)

zap65535(½ð±Ò+0,VIP+0):¿ÉÒÔȥרҵ°æ¿éÌáÎÊ 12-27 01:57
·Ç³£¸Ðл£¡£¡£¡ÎÒÏëÓÃDGK-IV»ùÒòתȾÐļ¡Ï¸°û£¬²»ÖªµÀÕâλÅóÓÑÄܲ»ÄÜÔÚÕâ·½ÃæÖ¸µãһϣ¡£¡£¡±¾È˷dz£¸Ðл£¡£¡£¡ÄãÄܸøÎÒ»ØÌû£¬ÎÒÏàÐÅÎÒÃÇÊÇÓÐÔµµÄ£¡£¡£¡
4Â¥2009-12-27 00:12:18
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

sophia622

ľ³æ (СÓÐÃûÆø)

²»ºÃÒâ˼  ÎÒ²»ÊÇѧÕâ·½ÃæµÄ
5Â¥2009-12-27 11:56:52
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] Ò»Ö¾Ô¸±±¾©»¯¹¤´óѧ£¬³õÊԳɼ¨350Çóµ÷¼Á +9 ÑØ°¶?±´¿Ç 2026-04-04 14/700 2026-04-05 01:09 by ÑØ°¶?±´¿Ç
[¿¼ÑÐ] Ò»Ö¾Ô¸Ö£ÖÝ´óѧ²ÄÁÏÓ뻯¹¤085600£¬Çóµ÷¼Á +24 ³ÔµÄ²»ÉÙ 2026-04-02 24/1200 2026-04-04 23:20 by ÓÀ×ÖºÅ
[¿¼ÑÐ] 295Çóµ÷¼Á +4 AÄãºÃÑо¿Éú 2026-04-04 5/250 2026-04-04 22:46 by yu221
[¿¼ÑÐ] ÇóÉúÎïѧµ÷¼Á +14 15172915737 2026-04-01 14/700 2026-04-04 20:13 by babysonlkd
[¿¼ÑÐ] Ò»Ö¾Ô¸»ª±±µçÁ¦´óѧ£¨±±¾©£©£¬²ÄÁÏ¿ÆÑ§Ó빤³Ìѧ˶265£¬Çóµ÷¼Á +11 yelck 2026-04-03 12/600 2026-04-04 19:52 by dongzh2009
[¿¼ÑÐ] 081200-11408-276ѧ˶Çóµ÷¼Á +5 ´Þwj 2026-03-31 5/250 2026-04-04 19:45 by 1753564080
[¿¼ÑÐ] ÍÁľ304Çóµ÷¼Á +4 ÍÃͻͻͻ£¬ 2026-03-31 4/200 2026-04-04 13:34 by 1753564080
[¿¼ÑÐ] Ò»Ö¾Ô¸Äϲý´óѧ324Çóµ÷¼Á +9 hanamiko 2026-03-30 9/450 2026-04-04 11:04 by Öí»á·É
[¿¼ÑÐ] 320Çóµ÷¼Á +5 Õñ¡ªTZ 2026-04-02 5/250 2026-04-03 14:42 by fxue1114
[¿¼ÑÐ] 275Çóµ÷¼Á +14 waltzh 2026-04-01 14/700 2026-04-03 11:24 by qqq850810
[¿¼ÑÐ] Ò»Ö¾Ô¸Öйú¿ÆÑ§Ôº´óѧ265Çóµ÷¼Á +9 Ìñµ­ye 2026-03-31 10/500 2026-04-03 11:10 by txp1986
[¿¼ÑÐ] 316Çóµ÷¼Á +14 ÖÛ×Ô¹£ 2026-04-01 18/900 2026-04-03 10:28 by linyelide
[¿¼ÑÐ] һ־Ըɽ¶«´óѧ»¯Ñ§Ó뻯¹¤Ñ§Ôº²ÄÁÏÓ뻯¹¤×¨Ë¶£¬360·ÖÇóµ÷¼Á +4 ²»Ô¸Í¸Â¶ÐÕÃûµÄË 2026-04-02 4/200 2026-04-03 09:29 by ÒÅÍüÏûʧµÄž™
[¿¼ÑÐ] Ò»Ö¾Ô¸»ªÄÏʦ·¶´óѧ-22408¼ÆËã»ú-292·Ö-Çó»ªÄÏʦ·¶´óѧµ÷¼Á +4 °®¶ÁÊéµÄСöùÓã 2026-04-02 4/200 2026-04-02 18:35 by Çóµ÷¼Ázz
[¿¼ÑÐ] 337Çóµ÷¼Á +11 ¡¶Ê÷¡· 2026-03-29 11/550 2026-04-02 10:20 by ²»³Ôô~µÄ؈
[¿¼ÑÐ] 310·ÖÇóµ÷¼Á +4 ³É¹¦Éϰ¶wang 2026-04-01 4/200 2026-04-01 20:35 by liu823948201
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤£¨0856£©304ÇóBÇøµ÷¼Á +8 Çñgl 2026-03-30 16/800 2026-04-01 17:58 by Çñgl
[¿¼ÑÐ] »·¾³¹¤³Ìµ÷¼Á +9 hyzzzzzzz. 2026-04-01 9/450 2026-04-01 14:20 by salamander`
[¿¼ÑÐ] 288×ÊÔ´Óë»·¾³×¨Ë¶Çóµ÷¼Á£¬²»ÏÞרҵ£¬ÓÐѧÉϾÍÐÐ +25 lllllos 2026-03-30 26/1300 2026-04-01 09:52 by Ò»Ö»ºÃ¹û×Ó?
[¿¼ÑÐ] ÉúÎÑÐ337·ÖÇóµ÷¼Á +4 cgxin 2026-03-30 6/300 2026-03-31 14:18 by ¼Çʱ¾2026
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û